|Mr. Daniel Mark Bradbury||Exec. Chairman||92.19k||N/A||1961|
|Mr. Bruce D. Steel C.F.A.||Co-Founder, Pres, CEO & Director||414.42k||N/A||1966|
|Dr. Stephen Connelly Ph.D.||Chief Scientific Officer & Director||516.61k||N/A||1982|
|Dr. Krishna R. Polu||Consultant||612k||N/A||1973|
|Mr. Jason A. Keyes||Chief Financial Officer||N/A||N/A||1971|
|Ms. Christine Zedelmayer M.B.A., P.M.P.||Sr. VP & COO||N/A||N/A||1970|
|Mr. Michael Moore||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Matthew Ritter Ph.D.||VP of Corp. Devel.||N/A||N/A||N/A|
|Mr. Joel M. Rothman||Chief Devel. Officer||N/A||N/A||1969|
|Dr. Dolca Thomas M.D.||Exec. VP of R&D and Chief Medical Officer||N/A||N/A||1971|
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Equillium, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.